Kjell Simonsson, MD, B.Sc. in Business and Administration, has worked within the Life Science sector for more than a quarter of a century. Dr. Simonsson most recently held the position as Managing Director at Karolinska Investment Fund, a position he held since its establishment in 1999. Karolinska Investment Fund was a Venture Capital Fund investing in Life Science companies funded by Karolinska Institutet and Alecta in 1999 and managed by Dr. Simonsson for more than ten years.

Kjell Simonsson has a strong background and experience from several parts of the Life Science sector. He started out as a clinician, is a specialist in anesthesiology and intensive care, and has worked clinically for more than a decade. Dr. Simonsson has worked within in the medtech industry in both marketing and medical positions. In 1997 he joined Aragon Fondkommission AB and established, built and managed a large analytical team focusing on Life Science and giving advice to private investors as well as corporations. At Aragon, Dr. Simonsson worked closely with the Corporate Finance division and was involved in several Life Science transactions. In 1999 he left to help establish and manage one of the first Venture Capital Funds in Scandinavia solely focusing on the Life Science sector.

Kjell Simonsson has over the years participated in a large amount of equity capital market transactions. He has on behalf of Karolinska Investment Fund invested, restructured and divested several Life Science companies. Dr. Simonsson has served as chairman, director and deputy director of several boards, eg. Carema ( Ambea), Lipocore, Gyros, Independent Pharmaceutica, Sidec Technologies, Demetech, Radiumhospitalets Forskningsstiftelse, Kavatvård, KI Management AB, Ultraljudbarnmorskorna etcetera.

Kjell Simonsson holds a B.Sc. in Business and Administration from Stockholm School of Economics and is a Specialist in Anesthesiology and Intensive Care from Karolinska Institutet in Stockholm.